Mechanistic understanding of antibiotic action can yield crucial insights that aid in the design of new antibiotics. In this issue, Mukhopadhyay et al. (2008) uncover the mechanism by which the antibiotic myxopyronin inhibits bacterial RNA polymerase, suggesting a new target region in RNA polymerase for inhibitor design. Cell, describing the mechanism of bacterial RNAP inhibition by the α-pyrone antibiotic myxopyronin (myx), which is produced by the bacteria Myxococcus fulvus (Irschik et al., 1983) .
Given the implications for human health, the development of antibiotic resistance in pathogenic bacteria is a topic of more than academic interest. The emergence of bacterial strains resistant to rifamycins, a group of antibiotics that inhibit the bacterial RNA polymerase (RNAP), has greatly compromised the treatment of tuberculosis. Rifamycins are the only antibiotics in widespread use to treat tuberculosis (Shinnick, 1996) , a disease that is estimated by the World Health Organization to have killed 1.7 million people in 2006 alone. Thus, there is an urgent need to develop new antibiotics to treat infections caused by rifamycin-or multidrug-resistant bacteria. The bacterial RNAP is an attractive target for development of such drugs (Chopra, 2007) . As a large multisubunit enzyme, RNAP is expected to have multiple sites that could be bound by small molecules. Also, although the transcriptional machinery of prokaryotes and eukaryotes exhibits similarities in structure and mechanism, there has been sufficient divergence in even the most conserved RNAP subunits to make specific targeting of bacterial or eukaryotic RNAPs possible. Indeed, several antibiotics that specifically inhibit bacterial RNAP or eukaryotic RNAP II have been found to occur naturally; rifamycins are one such example (Campbell et al., 2001 Gnatt et al., 2001 ) and open (B; PDB 1I3Q, Cramer et al., 2000) conformations. RNAP converts between open and closed confirmations by the 30° rotation of the clamp domain (cyan) around the switch region located at the base of the clamp. The clamp domain is formed by part of the largest RNAP subunit (β' in bacterial RNAP; RPB1 in eukayotic RNAP II). Clamp opening is required to allow DNA to bind in the catalytic cleft (C) and is followed by clamp closure (D; PDB 2VUM, Brueckner and Cramer, 2008 ) in a step coupled to promoter melting to allow transcription initiation. The antibiotic myxopyronin (myx) binds in the switch (E; PDB 3DXJ, Mukhopadhyay et al., 2008) and blocks clamp opening to prevent DNA binding.
Cell, describing the mechanism of bacterial RNAP inhibition by the α-pyrone antibiotic myxopyronin (myx), which is produced by the bacteria Myxococcus fulvus (Irschik et al., 1983) .
RNAP resembles a crab claw (Figure 1A) that must open to allow DNA to bind in the catalytic cleft. It does so via a swinging motion of one of the "pincers" (the clamp) that is formed by part of the largest RNAP subunit (β′ in bacterial RNAP; RPB1 in eukayotic RNAP II) ( Figures 1B and 1C) . Following DNA binding, the clamp swings back to close over the DNA ( Figure 1D ) in a step that appears coupled to promoter melting during transcription initiation. This step is also likely to be required for transcription complex stability and processivity during transcription elongation. To study how RNAP is inhibited by myx, Mukhopadhyay et al. needed to find the myxbinding site. A screen for myx resistance in the bacteria Escherichia coli uncovered mutations in three RNAP residues in the switch region that forms the hinge around which the clamp rotates to open and close the DNA-binding cleft. The authors then performed targeted mutagenesis of the RNAP switch region in E. coli to identify residues that, when mutated, confer myx resistance. In the 125 myx-resistant E. coli strains they identified, the authors found 13 residues within the switch region whose individual mutation conferred resistance to myx. Remarkably, all 13 of these residues are conserved in the RNAPs of different bacteria, thus explaining myx's broad spectrum activity against both Gram-positive and Gram-negative pathogens. Furthermore, consistent with myx's bacteriaspecific inhibitory activity, 3 of these 13 residues are not conserved in eukaryotic RNAPs.
Binding experiments showed that mutations in any of these 13 residues disrupted myx binding, thus implicating the switch region as the site of myx binding. Mukhopadhyay and colleagues confirmed this mode of myx binding by determining the structure of RNAP from the bacteria Thermus thermophilus in a complex with myx. The structure revealed that myx is almost completely buried in a hydrophobic pocket within the switch, far from the catalytic center ( Figure 1E ). This suggested that myx functions allosterically by inhibiting either the opening or closing of the clamp. But was myx jamming the clamp's hinge to prevent clamp opening and DNA binding, or was it binding to the opened clamp to prevent clamp closure after DNA has bound? Although the crystal structure implied the former scenario, it was possible that this aspect of the structure was misleading given that crystal packing can alter protein conformations from their state in solution. To distinguish between these two possibilities, Mukhopadhyay et al. characterized the effects of myx on RNAP promoter binding in vitro. They found that myx inhibited promoter binding only if it was added to the in vitro reaction containing RNAP before the promoter DNA was added. If myx was added after the promoter DNA was introduced into the reaction, no binding inhibition was observed. Moreover, myx had similar inhibitory effects on both abortive (short) and runoff (long) transcript synthesis in vitro, consistent with myx inhibiting DNA binding rather than affecting transcription complex stability or processivity following DNA binding. Furthermore, myx did not inhibit RNAP binding to promoters that lacked the DNA duplex region usually bound within the RNAP "claw" and melted during transcription initiation, implying that myx locks the clamp in a closed or partially closed state that still allows the RNAP to accommodate a single strand of DNA but not a duplex.
This characterization of the mechanism of RNAP inhibition by myx has further implications for the mode of action of two other antibiotics, corallopyronin and ripostatin. Mukhopadhyay et al. showed that both of these antibiotics have identical patterns of inhibition and order-of-addition effects in promoter-binding experiments. Thus, it is likely that these antibiotics have a mechanism akin to myx-binding in the RNAP switch region to block clamp opening and promoter binding. Indeed, almost without exception, mutant E. coli resistant to any one of these three antibiotics are also resistant to the other two. This is particularly surprising for ripostatin, a macrocylic-lactone molecule that, unlike corallopyronin, is similar to myx only in terms of size and general hydrophobicity.
Other compounds inhibit RNAP by interfering with conformational changes. For example, streptolydigin binds to bacterial RNAP near the base of the pincer opposite the clamp and is believed to function by inhibiting the conformational changes required to organize the RNAP catalytic center or to translocate the RNAP during each cycle of nucleotide addition (Tuske et al., 2005) . The toxin of the death cap mushroom, α-amanitin, binds to eukaryotic RNAP II in a region near the streptolydigin-binding site and has been proposed to work via a similar mechanism (Kaplan et al., 2008) . Why might sites of focused conformational change be preferentially targeted by these naturally occurring inhibitors? Most obviously, jamming the moving parts of the transcription machine, like jamming the moving parts of any machine, is an effective way to stop it in its tracks. But there may be other features of these sites that make them ready targets for small-molecule inhibitors. As points of articulation between different RNAP domains or subdomains, these sites may be like the chinks in a suit of armor-weak points where a sword can be driven in. Indeed, myx is bound in the switch region in a manner that suggests it has wormed its way into this site, a mechanism that would require RNAP flexing to allow myx binding. This study is the latest chapter in a two decade long effort to understand RNAP structure and mechanism. With the myx-RNAP structure in hand, Mukhopadhyay et al. can now propose rational modifications that should enhance myx affinity and effectiveness in RNAP inhibition. This next step can only be contemplated because of the advance in understanding of myx mechanism achieved through a comprehensive approach that brought together genetics, biochemistry, and crystallography. Mechanistic understanding is the prerequisite to manipulating what nature has provided. To paraphrase Al Pacino in the film Scarface, when you get the knowledge, then you get the power.
Mukhopadhyay, J., Das, K., Ismail, S., Koppstein, D., Jang, M., Hudson, B., Sarafianos, S., Tuske, S., Patel, J., Jansen, R., et al. (2008) . Cell, this issue. Shinnick, T., ed. (1996) . Current Topics in Microbiology and Immunology (New York: SpringerVerlag).
Tuske, S., Sarafianos, S.G., Wang, X., Hudson, B., Sineva, E., Mukhopadhyay, J., Birktoft, J.J., Leroy, O., Ismail, S., Clark, A.D., Jr., et al. (2005) . Cell 122, 541-552.
During gene transcription, the initial transcript generated is processed into functional messenger RNAs (mRNAs) by enzymes directly recruited to the RNA polymerase II (Pol II) elongation complex and is also simultaneously packaged into RNA-protein complexes (mRNPs) (reviewed in Egloff and Murphy, 2008) . With the advances in experimental techniques such as chromatin fractionation and nuclear imaging using fluorescent markers for DNA, RNA, or protein, remarkable progress has been made in the understanding of how this process of nuclear gene transcription transitions seamlessly to the production of proteins in the cytoplasm (for example, see Janicki et al., 2004) . It is widely thought that the packaging and processing of nuclear mRNA during transcription is directly coupled to its export through the nuclear pore complex (NPC) for translation in the cytoplasm (reviewed in Vinciguerra and Stutz, 2004) . Given that the NPC is responsible not only for the export of mRNPs but also for both export and import of many proteins, including fully assembled ribosomes, it is likely that NPC access is a rate limiting step in gene expression. In budding yeast Saccharomyces cerevisiae, the mRNA packaging complex THO and RNA helicase Sub2 associate with mRNA export factors to form the TREX (Transcription/Export) complex that targets mRNA to the NPC (Strässer et al., 2002) . In this issue of Cell, a study by Rougemaille et al. (2008) now suggests a role for THO/Sub2 in coordinating the events that prepare an mRNA for export.
As with all routes that encounter heavy traffic, elaborate mechanisms must be in place at the NPC to prevent passage by illegitimate cargos, which might slow down the traffic or possibly result in blockage of the entire nuclear transport process with lethal consequences for the cell. Indeed, disruption of the mRNA processing machinery that ensures only functional mRNAs are exported through the NPC has already been well documented to negatively impact NPC function. It now seems that defects in mRNA packaging prior to export are linked to aberrant mRNA processing and also present problems for NPC function. A recent study demonstrated that the loss of the mRNA packaging functions of THO has a direct effect on mRNA 3′ end processing (Saguez et al. 2008) . Mutations in THO components that disrupt THO function appeared to slow down Pol II transcription over polyA signals at the 3′ ends of genes, as well as inhibit the maturation of the mRNA polyA tail. Intriguingly, this effect is at least in part due to the degradation of the polyA factor Fip1, a protein that links mRNA 3′ end cleavage with polyA addition during formation of the mRNA 3′ end. Thus, THO mutants display a defect in the 3′ processing of mRNA transcripts. In their study linking THO with the NPC, Rougemaille et al. now add to this understanding of the consequence of losing THO function.
Using a modified method of fractionating chromatin, Rougemaille and colleagues now establish a connection between mRNA packaging and the NPC. This work also highlights the potential biases inherent in analyzing chromatin with techniques such as chromatin immunoprecipitation (ChIP). The authors observed that heat shock genes in S. cerevisiae display an aberrant chromatin conformation in strains harboring mutations in the THO complex (tho strains) or in the THO-associated RNA helicase Sub2. Perplexingly, regular chromatin preparation techniques for ChIP, which include a centrifugation step at 18,000 g to remove cellular debris from the chromatin fraction, resulted in the loss of DNA from the 3′ regions of these heat shock genes. Interestingly, if the centrifugation step was performed at a lower speed of Nuclear Roadblocks for mRNA export Ana G. Rondon 1 and Nick J. Proudfoot 1,
